Literature DB >> 20392512

Involvement of microsomal triglyceride transfer protein in nonalcoholic steatohepatitis in novel spontaneous mouse model.

Nobuyasu Shindo1, Tomomi Fujisawa, Ken Sugimoto, Koji Nojima, Aya Oze-Fukai, Yuki Yoshikawa, Xiang Wang, Osamu Yasuda, Hiroshi Ikegami, Hiromi Rakugi.   

Abstract

BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD) is currently recognized as a global health issue and encompasses a wide spectrum of entities, ranging from simple hepatic steatosis to nonalcoholic steatohepatitis (NASH). The lack of a spontaneous animal model of NASH, however, has hampered basic research in this field.
METHODS: We examined the hepatic lesions in the inbred Fatty Liver Shionogi (FLS) mouse, which exhibits type 2 diabetes, and investigated the molecular mechanism leading to NAFLD/NASH. Using vector-mediated hepatic expression of microsomal triglyceride transfer protein (MTP), a key molecule for very low density lipoprotein (VLDL) assembly and export, its contribution to the hepatic lesions as well as to glucose intolerance was examined.
RESULTS: The FLS mouse, maintained on normal chow, exhibited excessive hepatic triglyceride (TG) accumulation due to impaired VLDL secretion, and subsequently hepatic lesions comparable to NASH, with increased expression of inflammatory molecules as well as insulin resistance. Gene expression and Western blot analyses demonstrated reduced hepatic expression of MTP in the FLS mouse. Hepatic induction of MTP resulted in a reduction in hepatic TG accumulation, improvement of VLDL export, and amelioration of NASH-like lesions, as well as glucose intolerance.
CONCLUSIONS: These data suggest that the FLS mouse could serve as a spontaneous model of NASH with insulin resistance, and that reduced MTP is involved in the development of NASH, pointing towards MTP as a critical target for the prevention and treatment of NASH. Copyright 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20392512     DOI: 10.1016/j.jhep.2009.12.033

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  16 in total

1.  Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet.

Authors:  Jamie E Mells; Ping P Fu; Shvetank Sharma; Darin Olson; Lihong Cheng; Jeffrey A Handy; Neeraj K Saxena; Dan Sorescu; Frank A Anania
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-10-28       Impact factor: 4.052

2.  MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis.

Authors:  Wei-Chih Tsai; Sheng-Da Hsu; Chu-Sui Hsu; Tsung-Ching Lai; Shu-Jen Chen; Roger Shen; Yi Huang; Hua-Chien Chen; Chien-Hsin Lee; Ting-Fen Tsai; Ming-Ta Hsu; Jaw-Ching Wu; Hsien-Da Huang; Ming-Shi Shiao; Michael Hsiao; Ann-Ping Tsou
Journal:  J Clin Invest       Date:  2012-07-23       Impact factor: 14.808

Review 3.  The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes.

Authors:  Rachel J Perry; Varman T Samuel; Kitt F Petersen; Gerald I Shulman
Journal:  Nature       Date:  2014-06-05       Impact factor: 49.962

4.  Gene Expression Analysis of the Activating Factor 3/Nuclear Protein 1 Axis in a Non-alcoholic Steatohepatitis Mouse Model.

Authors:  Ran Nagahara; Tomomitsu Matono; Takaaki Sugihara; Yukako Matsuki; Masafumi Yamane; Toshiaki Okamoto; Kenichi Miyoshi; Takakazu Nagahara; Jun-Ichi Okano; Masahiko Koda; Hajime Isomoto
Journal:  Yonago Acta Med       Date:  2019-03-28       Impact factor: 1.641

5.  Deficiency of iNOS-derived NO accelerates lipid accumulation-independent liver fibrosis in non-alcoholic steatohepatitis mouse model.

Authors:  Yuichi Nozaki; Koji Fujita; Koichiro Wada; Masato Yoneda; Takaomi Kessoku; Yoshiyasu Shinohara; Kento Imajo; Yuji Ogawa; Makoto Nakamuta; Satoru Saito; Naohiko Masaki; Yoji Nagashima; Yasuo Terauchi; Atsushi Nakajima
Journal:  BMC Gastroenterol       Date:  2015-04-01       Impact factor: 3.067

6.  The effect of the severity of liver cirrhosis on the level of lipids and lipoproteins.

Authors:  Lech Chrostek; Lukasz Supronowicz; Anatol Panasiuk; Bogdan Cylwik; Ewa Gruszewska; Robert Flisiak
Journal:  Clin Exp Med       Date:  2014-11       Impact factor: 3.984

7.  Ezetimibe prevents the development of non‑alcoholic fatty liver disease induced by high‑fat diet in C57BL/6J mice.

Authors:  Xiang Wang; Qiaohua Ren; Tao Wu; Yong Guo; Yong Liang; Subo Liu
Journal:  Mol Med Rep       Date:  2014-10-10       Impact factor: 2.952

8.  The FLS (fatty liver Shionogi) mouse reveals local expressions of lipocalin-2, CXCL1 and CXCL9 in the liver with non-alcoholic steatohepatitis.

Authors:  Toshihisa Semba; Motoi Nishimura; Satomi Nishimura; Osamu Ohara; Takayuki Ishige; Sayaka Ohno; Ken Nonaka; Kazuyuki Sogawa; Mamoru Satoh; Setsu Sawai; Kazuyuki Matsushita; Fumio Imazeki; Osamu Yokosuka; Fumio Nomura
Journal:  BMC Gastroenterol       Date:  2013-07-23       Impact factor: 3.067

Review 9.  Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse.

Authors:  Jesse D Riordan; Joseph H Nadeau
Journal:  Mamm Genome       Date:  2014-05-07       Impact factor: 2.957

10.  Tree shrew (Tupaia belangeri chinensis), a novel non-obese animal model of non-alcoholic fatty liver disease.

Authors:  Linqiang Zhang; Xiaoyun Wu; Shasha Liao; Yunhai Li; Zhiguo Zhang; Qing Chang; Ruyue Xiao; Bin Liang
Journal:  Biol Open       Date:  2016-10-15       Impact factor: 2.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.